Anti-IL-11 drug extends lifespan by over 20% in mice
Scientists have discovered that ‘switching off’ protein interleukin 11 (IL-11) can significantly increase the healthy lifespan of mice by almost 25%.
The scientists at the Medical Research Council Laboratory of Medical Science (MRC LMS) and Imperial College London, working with colleagues at Duke-NUS Medical School in Singapore, created mice that had the gene producing IL-11 deleted.
This extended the lives of the mice by over 20% on average.
They also treated 75-week-old mice – equivalent to the age of about 55 years in humans – with an injection of an anti-IL-11 antibody.
The results, published in Nature, were dramatic, with mice given the anti-IL-11 drug from 75 weeks of age until death having their median lifespan extended by 22.4% in males and 25% in females.
The treatment largely reduced deaths from cancer in the animals, as well as reducing the many diseases caused by fibrosis, chronic inflammation and poor metabolism.
Professor Stuart Cook, from the MRC LMS, Imperial College London and Duke-NUS Medical School in Singapore, said: “These findings are very exciting. The treated mice had fewer cancers, and were free from the usual signs of ageing and frailty, but we also saw reduced muscle wasting and improvement in muscle strength.
“Previously proposed life-extending drugs and treatments have either had poor side-effect profiles, or don’t work in both sexes, or could extend life, but not healthy life, however this does not appear to be the case for IL-11.
“While these findings are only in mice, it raises the tantalising possibility that the drugs could have a similar effect in elderly humans. Anti-IL-11 treatments are currently in human clinical trials for other conditions, potentially providing exciting opportunities to study its effects in ageing humans in the future.”
IL-11 levels increase with age
The researchers have been investigating IL-11 for many years. In 2018, they were the first to show that IL-11 is a pro-fibrotic and pro-inflammatory protein, overturning years of incorrect characterisation as anti-fibrotic and anti-inflammatory.
Previously, scientists have posited that IL-11 is an evolutionary hangover in humans, as while it is vital for limb regeneration in some animal species, it is thought to be largely redundant in humans.
However, after about the age of 55 in humans, more IL-11 is produced and past research has linked this to chronic inflammation, fibrosis in organs, disorders of metabolism, muscle wasting (sarcopaenia), frailty, and cardiac fibrosis.
The research has proved that IL-11 causes multimorbidity and frailty, among the biggest global healthcare challenges of the 21st century. Currently, no treatment for multimorbidity is available, other than to try to treat the separate multiple underlying causes individually.
Diana Spencer, Senior Digital Content Editor, DDW
